Neuralstem Inc. (CUR) and OPKO Health Inc. (NASDAQ:OPK) Comparison side by side

Neuralstem Inc. (NASDAQ:CUR) and OPKO Health Inc. (NASDAQ:OPK) compete with each other in the Biotechnology sector. We will analyze and compare their risk, analyst recommendations, profitability, institutional ownership, dividends, earnings and valuation.

Earnings and Valuation Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Neuralstem Inc. N/A 18.22 7.92M -0.52 0.00 OPKO Health Inc. 1.03B 1.60 298.50M -0.52 0.00 Table 1 shows the top-line revenue, earnings per share (EPS) and valuation for Neuralstem Inc. and OPKO Health Inc.


Table 2 has Neuralstem Inc. and OPKO Health Inc.’s net margins, return on equity and return on assets. Neuralstem Inc. 0.00% -123.1% -74.7% Risk and Volatility

A beta of 1.84 shows that Neuralstem Inc. is 84.00% more volatile than Standard and Poor’s 500. OPKO Health Inc.’s 2.02 beta is the reason why it is 102.00% more volatile than Standard and Poor’s 500.


The current Quick Ratio of Neuralstem Inc. is 5.5 while its Current Ratio is 5.5. Meanwhile, OPKO Health Inc. has a Current Ratio of 0.9 while its Quick Ratio is 0.8. Neuralstem Inc. is better positioned to pay off its short-term and long-term debts than OPKO Health Inc.

Institutional & Insider Ownership

Roughly 6.3% of Neuralstem Inc. shares are owned by institutional investors while 27.5% of OPKO Health Inc. are owned by institutional investors. About 0.3% of Neuralstem Inc.’s share are owned by insiders. On the other hand, insiders owned about 5.1% of OPKO Health Inc.’s shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders. Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD) Neuralstem Inc. -14.71% -24.96% -62.7% -74.46% -80.85% -75.06% OPKO Health Inc. -11.23% -13.99% -43.34% -19.61% -36.28% -32.24% For the past year Neuralstem Inc.’s stock price has bigger decline than OPKO Health Inc.

Neuralstem, Inc., a clinical stage biopharmaceutical company, focuses on the research and development of nervous system therapies based on its proprietary human neuronal stem cells and small molecule compounds. The companyÂ’s stem cell based technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. It is developing products include NSI-189, a chemical entity, which is in Phase II clinical trial for the treatment of major depressive disorder, as well as is in preclinical programs for the MCAO stroke, type 1 and 2 diabetes related neuropathy, irradiation-induced cognition, long-term potentiation enhancement, and angelman syndrome. The company is also developing NSI-566, which has completed Phase II clinical trial for treating amyotrophic lateral sclerosis disease, as well as is in Phase I clinical trials for the treatment of chronic spinal cord injury and motor deficits due to ischemic stroke. Neuralstem, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, and Mexico. The companyÂ’s Diagnostics segment operates Bio-Reference Laboratories, a clinical laboratory that offers laboratory testing services in the detection, diagnosis, evaluation, monitoring, and treatment of diseases. The Bio-Reference Laboratories also provides core genetic testing and leverage products, such as the 4Kscore prostate cancer test and the Claros 1 in-office immunoassay platform. The companyÂ’s pharmaceutical segment offers Rayaldee, a treatment for secondary hyperparathyroidism in adults with stage 3-4 chronic kidney disease patients with vitamin D deficiency; and VARUBI for chemotherapy-induced nausea and vomiting. This segment is also developing TT401, which is in Phase II clinical trials for type 2 diabetes and obesity; TT701, an androgen receptor modulator that is in Phase II clinical trials for androgen deficiency indications; and hGH-CTP, a growth hormone injection that is in Phase III clinical trials. In addition, it engages in developing and commercializing hGH-CTP, a recombinant human growth hormone product that is in Phase III; developing Factor VIIa drug for hemophilia that is in Phase IIa, an NK-1 compound, and drugs for treating asthma and chronic obstructive pulmonary disease; developing and producing specialty active pharmaceutical ingredients; and discovery of drugs for the treatment of cancer, heart disease, metabolic disorders, and a range of genetic anomalies. Further, this segment engages in the development, manufacture, and sale of pharmaceutical, nutraceutical, and veterinary products; and markets and distributes pharmaceutical and natural products. Additionally, OPKO Health, Inc. operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was incorporated in 1991 and is headquartered in Miami, Florida.

Click Here to Continue...

Add a Comment

Your email address will not be published. Required fields are marked *